Citation Main C, Pitt M, Moxham T, Stein K. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. Health Technology Assessment 2010; 14(Suppl 2 Article 4): 27-32 Authors' objectives <p>This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia (CLL) based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process.</p> Authors' conclusions At the time of writing, the Appraisal Consultation Document issued by NICE on 26 March 2009 states that:Rituximab in combination with fludarabine and cyclophosphamide (R-FC) is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia in people for whom fludarabine in combination with cyclophosphamide (FC) is considered appropriate. Rituximab in combination with chemotherapy agents other than fludarabine and cyclophosphamide is not recommended for the first-line treatment of chronic lymphocytic leukaemia. Indexing Status Subject indexing assigned by NLM MeSH Antibodies, Monoclonal, Murine-Derived /administration & Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Cost-Benefit Analysis; Cyclophosphamide /administration & Great Britains; Leukemia, Lymphocytic, Chronic, B-Cell /drug therapy /economics; Randomized Controlled Trials as Topic; Rituximab; Vidarabine /administration & derivatives /economics; dosage /analogs & dosage /economics; dosage /economics Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32011000921 Date abstract record published 22/06/2011 |